Merck & Co., Inc.'s ROTATEQ(R) Reduced Hospitalizations and Emergency Department Visits Due to G9P1A(8) Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--The prescribing information for Merck & Co., Inc.'s ROTATEQ® (rotavirus vaccine, live, oral pentavalent), the only vaccine in the U.S. to help prevent rotavirus gastroenteritis in infants and children caused by G1-G4 serotypes, now includes data showing that ROTATEQ reduced hospitalizations and emergency department visits caused by the G9P1A[8] rotavirus serotype, by 100 percent (zero cases were seen in those who received ROTATEQ compared with 14 cases in placebo recipients). These data are from a post-hoc analysis of healthcare utilization data from more than 68,000 infants in the Rotavirus Efficacy and Safety Trial (REST), one of the largest pre-licensure vaccine clinical trials ever conducted.